BRIEF-AcelRx Pharmaceuticals says ARX-04 phase 3 trial met primary endpoint
August 15, 2016 at 07:10 AM EDT
* Overall ARX-04 was well tolerated in study, with 79% of patients reporting no adverse events
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.